RAYMOND JAMES & ASSOCIATES - GALECTIN THERAPEUTICS INC ownership

GALECTIN THERAPEUTICS INC's ticker is GALT and the CUSIP is 363225202. A total of 59 filers reported holding GALECTIN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of GALECTIN THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$51,000
-31.1%
13,096
-52.8%
0.00%
Q3 2020$74,000
-12.9%
27,7400.0%0.00%
Q2 2020$85,000
+57.4%
27,7400.0%0.00%
Q1 2020$54,000
-31.6%
27,7400.0%0.00%
Q4 2019$79,000
-20.2%
27,740
+2.4%
0.00%
Q3 2019$99,000
+65.0%
27,090
+49.8%
0.00%
Q4 2017$60,00018,0900.00%
Other shareholders
GALECTIN THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Cutter & CO Brokerage, Inc. 184,742$401,0000.10%
Geneos Wealth Management Inc. 511,606$2,261,0000.06%
SHEPHERD KAPLAN KROCHUK, LLC 12,000$26,0000.01%
OCCUDO QUANTITATIVE STRATEGIES LP 18,967$41,0000.01%
Vivaldi Capital Management LP 10,668$45,0000.01%
OSAIC HOLDINGS, INC. 1,221,984$2,651,0000.01%
CENTAURUS FINANCIAL, INC. 15,614$34,0000.00%
WEDBUSH SECURITIES INC 17,998$39,0000.00%
D.A. DAVIDSON & CO. 65,310$142,0000.00%
Virtu Financial LLC 14,683$32,0000.00%
View complete list of GALECTIN THERAPEUTICS INC shareholders